Protective effect of geranylgeranylacetone against radiation-induced delayed effects on human keratinocytes.

Skin exposure to ionizing radiation affects the normal wound healing process. We investigated the beneficial effects of a pharmacological treatment with geranylgeranylacetone (GGA) on keratinocytes using in vitro scratch wound injury assay in nonirradiated and irradiated conditions. Irradiation affected the wound closure of keratinocytes 24 h after scratch injury, whereas re-epithelialization was markedly accelerated after GGA treatment when compared to nontreated keratinocytes. We demonstrated that GGA treatment increased migration of human epidermal keratinocytes and this migratory property was not related to RhoA signaling. Interestingly, Western blot analysis revealed that GGA treatment down-regulated caspase 3 active form expression and up-regulated the activated phenotype by inducing both keratin 6 (K6) expression and interleukin-1ß (IL-1ß) release without modification of the differentiate phenotype. Finally, the proteomic profiling was performed on keratinocytes, showing that global protein changes occurred after irradiation of keratinocytes treated or untreated with GGA.

Cosmeceuticals and active ingredients.

Cosmetic ingredients previously considered "inert" have potential to provide a biologic effect to skin. In a cosmeceutical formulation, the boundary between an "active" and "inert" ingredient may be obscured. For this reason, the cosmeceutical distributor must find a nonambiguous method to demonstrate the efficacy of a new ingredient. For a product to be successful in the marketplace, the benefits of the product must clearly be communicated to the consumer, and the consumer must be satisfied with product performance.